Evaluation of siramesine, β-Lapachone, and palbociclib as novel maintenance therapies after chemotherapy in small cell lung cancer.

Small cell lung cancer (SCLC) represents approximately 15 % of all lung cancer cases and is characterized by rapid proliferation and a high metastatic potential. In the search for new treatments, drug repurposing has gained increasing attention, part…

Preview only. Read the full abstract at the source